Doctor Mikhail Kosiborod
St. Luke's Mid America Heart Institute, Kansas City (United States of America)
The obesity phenotype of HFpEF: new therapies on our door step?
Event: ESC Congress 2023
Topic: Chronic Heart Failure
Session type: Satellite Symposium
Finerenone: a disease-modifying therapy for heart and kidney protection
Event: ESC Congress 2023
Topic: Clinical
Session type: Satellite Symposium
Tackling the risk of hyperkalaemia through guideline-recommended heart failure therapy
Event: ESC Congress 2023
Topic: Chronic Heart Failure
Session type: Satellite Symposium
HFpEF: a great unmet need?
Event: Heart Failure 2023
Topic: Chronic Heart Failure
Session type: Satellite Symposium
Breaking barriers in guideline-based RAASi-therapy: solving issues with hyperkalemia
Event: Heart Failure 2023
Topic: Treatment
Session type: Satellite Symposium
What's the next STEP in HFpEF?
Event: Heart Failure 2022
Topic: Chronic Heart Failure
Session type: Satellite Symposium
Glucagon-like peptide 1 receptor agonists in clinical cardiology practice
Event: ESC Congress 2021 - The Digital Experience
Topic: Risk Factors and Prevention
Session type: Satellite Symposium
Consequences of COVID-19 in heart failure: one year on
Event: ESC Congress 2021 - The Digital Experience
Topic: Chronic Heart Failure
Session type: Abstract Sessions
6 years on, what have we learned from Real World use of PCSK9i?
Event: ESC Congress 2021 - The Digital Experience
Topic: Lipids
Session type: Satellite Symposium
Experts on the spot: exploring new dimensions in glucagon-like peptide-1 receptor agonists and cardiovascular risk
Event: ESC Congress 2019
Topic: Cardiovascular Disease in Special Populations
Session type: Satellite Symposium - Experts on the Spot
ESC 365 is supported by
